The clinical research of anisodamine treatment of chronic severe hepatitis B
QU Zhang-shu
ZHANG Wei
TANG Li-juan
HE Li
XU Xiao-ping
Abstract：Objective To study the clinical efficacy of anisodamine as adjuvant therapy of chronic severe hepatitis B. Methods One hundred and fifty cases of chronic severe hepatitis B were randomly divided into control group (75cases) and treated group (75cases). The control group were given lamivudine 100 mg/d and conventional treatment. Meanwhile some patients accepted 1-3 times of the treatment of Plasma Exchange. Besides the treatment in control group,the treated group had anisodamine (20 mg every day by intravenous drip or injection 2 times every day). The mortality rate and the changes of serum (such as TBIL,ALT,etc)of two groups before treatment and two weeks,4 weeks,8 weeks after treatment were compared. Results The mortality rate of treatment group decreased significantly(18/75),compared with control group(30/75)(x2=4.41,P＜0.05). The liver function of survival cases in both two groups (57 cases of treatment group,45cases of control group)was restored gradually. But the serum indicators of liver function of the treatment group decreased more rapidly that those in control group at 2 weeks,4 weeks and 8 weeks after treatment(P＜0.01). Conclusion Anisodamine can restore the liver function and reduce mortality in the treatment of chronic severe hepatitis B.
Keywords：Hepatitis BAnisodamineTreatment outcome
Publication Date：2011-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)